IL166108A0 - Novel compounds pharmaceutical compositions containing same and methods of use for same - Google Patents

Novel compounds pharmaceutical compositions containing same and methods of use for same

Info

Publication number
IL166108A0
IL166108A0 IL16610805A IL16610805A IL166108A0 IL 166108 A0 IL166108 A0 IL 166108A0 IL 16610805 A IL16610805 A IL 16610805A IL 16610805 A IL16610805 A IL 16610805A IL 166108 A0 IL166108 A0 IL 166108A0
Authority
IL
Israel
Prior art keywords
same
methods
pharmaceutical compositions
compositions containing
novel compounds
Prior art date
Application number
IL16610805A
Other languages
English (en)
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of IL166108A0 publication Critical patent/IL166108A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/32Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16610805A 2002-07-09 2005-01-03 Novel compounds pharmaceutical compositions containing same and methods of use for same IL166108A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39458502P 2002-07-09 2002-07-09
PCT/US2003/021700 WO2004005277A1 (en) 2002-07-09 2003-07-09 Novel compunds, pharmaceutical compositions containing same, and methods of use for same

Publications (1)

Publication Number Publication Date
IL166108A0 true IL166108A0 (en) 2006-01-15

Family

ID=30115739

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16610805A IL166108A0 (en) 2002-07-09 2005-01-03 Novel compounds pharmaceutical compositions containing same and methods of use for same
IL190218A IL190218A0 (en) 2002-07-09 2008-03-17 Novel compounds, pharmaceutical compositions containing same, and methods of use for same

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL190218A IL190218A0 (en) 2002-07-09 2008-03-17 Novel compounds, pharmaceutical compositions containing same, and methods of use for same

Country Status (13)

Country Link
US (2) US7649012B2 (de)
EP (3) EP2386551A1 (de)
JP (3) JP2005533835A (de)
KR (1) KR101087559B1 (de)
CN (2) CN101602756B (de)
AU (1) AU2003265267B2 (de)
BR (1) BRPI0312649A2 (de)
CA (2) CA2491802C (de)
EA (1) EA013371B1 (de)
IL (2) IL166108A0 (de)
MX (1) MXPA05000365A (de)
SG (1) SG169236A1 (de)
WO (1) WO2004005277A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA007029B1 (ru) 2002-02-08 2006-06-30 Джон Хопкинс Юниверсити Скул Оф Медсин Стимуляция срт-1 как средство уменьшения веса
CN101721412A (zh) * 2002-07-09 2010-06-09 法斯根有限责任公司 治疗人和动物中微生物感染的方法
EP2386551A1 (de) * 2002-07-09 2011-11-16 Fasgen Inc. Neue Verbindungen, pharmazeutische Zusammensetzungen damit und Anwendungsverfahren dafür
RU2006146051A (ru) * 2004-05-26 2008-07-10 Фасджен Новые соединения, фармацевтические композиции на их основе и способы применения
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
WO2008057585A1 (en) * 2006-11-08 2008-05-15 Fasgen Llc Novel compounds, pharmaceutical compositions containing same, and methods of use for same
WO2008059214A1 (en) * 2006-11-13 2008-05-22 Astrazeneca Ab Bisamlde derivatives and use thereof as fatty acid synthase inhibitors
JP2011521978A (ja) * 2008-06-02 2011-07-28 ファスジェン, インコーポレイテッド 新規化合物、それを含む医薬組成物、およびこれらの使用方法
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8729239B2 (en) 2009-04-09 2014-05-20 Nuclea Biotechnologies, Inc. Antibodies against fatty acid synthase
WO2011019498A1 (en) * 2009-07-27 2011-02-17 The Trustees Of Princeton University Inhibition of glycerol-3-phosphate acyltransferase (gpat) and associated enzymes for treatment of viral infections
RU2012111354A (ru) 2009-08-26 2013-10-10 Санофи Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012135027A2 (en) * 2011-03-25 2012-10-04 The Research Foundation Of State University Of New York Thiolactone antibiotics
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
CN104662028B (zh) * 2012-06-25 2017-05-24 托马斯杰弗逊大学 对具有异常的脂肪生成信号的癌症进行治疗的组合物和方法
US20150099730A1 (en) * 2012-09-07 2015-04-09 Janssen Pharmaceutica, Nv Imidazolin-5-one derivative useful as fasn inhibitors for the treatment of cancer
PH12015502097B1 (en) 2013-03-13 2023-02-03 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
CA2968288A1 (en) 2014-11-20 2016-05-26 Vib Vzw Means and methods for treatment of early-onset parkinson's disease
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
CN114480521B (zh) * 2020-11-13 2024-07-26 中国科学院青岛生物能源与过程研究所 一种三氮菌素c的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496187A (en) * 1967-03-20 1970-02-17 American Home Prod N-(heterocyclyl)aconamides
US3472878A (en) * 1969-01-27 1969-10-14 American Home Prod N-(hydroxyaryl)aconamides
JPS5859920A (ja) * 1981-10-05 1983-04-09 Chugai Pharmaceut Co Ltd 生体防禦能賦活剤
US4565699A (en) * 1983-07-18 1986-01-21 The Upjohn Company Composition of matter and process
US4720503A (en) * 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
CH667655A5 (de) * 1986-09-24 1988-10-31 Lonza Ag Verfahren zur herstellung von 4-alkoxy-2(5h)-thiophenonen.
US4753871A (en) * 1986-12-12 1988-06-28 Eastman Kodak Company Cyan dye-forming couplers and photographic materials containing same
WO1988004652A1 (fr) * 1986-12-17 1988-06-30 Nippon Soda Co., Ltd. Composes heterocycliques possedant un squelette triketo
US5759791A (en) * 1989-01-17 1998-06-02 The Johns Hopkins University Cancer related antigen
US5759837A (en) 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
US5665874A (en) * 1989-01-17 1997-09-09 John Hopkins University Cancer related antigen
US5679801A (en) * 1991-04-12 1997-10-21 American Home Products Corporation Tetronic and thiotetronic acid derivatives as phospholipase A2 inhibitors
US5614551A (en) 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
BR9608229A (pt) * 1995-05-09 1998-12-29 Bayer Ag Cetoenóis alquil-dihalogenofenil-substituídos
US5981575A (en) 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
JPH10212284A (ja) * 1996-11-27 1998-08-11 Sagami Chem Res Center テトロン酸−3−カルボン酸誘導体、その製造方法、製造中間体、抗がん剤、及び蛋白脱リン酸化酵素阻害剤
US6391912B1 (en) 1996-12-12 2002-05-21 Bayer Aktiengesellschaft Substituted phenylketoenols
CO4970714A1 (es) * 1997-09-05 2000-11-07 Boehringer Mannheim Gmbh Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h) tiofenonas como agentes antitumorales
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
IT1315267B1 (it) * 1999-12-23 2003-02-03 Novuspharma Spa Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
GB0000131D0 (en) * 2000-01-06 2000-02-23 Univ Cardiff Thiolactomycin analogues,compositions containing the same and uses thereof
US6376682B1 (en) * 2000-02-01 2002-04-23 Takama System, Ltd. Compound with α-glucosidase inhibiting action and method for producing the same
WO2002087565A1 (en) 2001-05-02 2002-11-07 New York University Inhibition of pigmentation by inhibition of fatty acid synthase
EA007029B1 (ru) * 2002-02-08 2006-06-30 Джон Хопкинс Юниверсити Скул Оф Медсин Стимуляция срт-1 как средство уменьшения веса
EP2386551A1 (de) * 2002-07-09 2011-11-16 Fasgen Inc. Neue Verbindungen, pharmazeutische Zusammensetzungen damit und Anwendungsverfahren dafür
CN101721412A (zh) 2002-07-09 2010-06-09 法斯根有限责任公司 治疗人和动物中微生物感染的方法
US9690894B1 (en) 2015-11-02 2017-06-27 Altera Corporation Safety features for high level design

Also Published As

Publication number Publication date
JP2011037881A (ja) 2011-02-24
EA200500178A1 (ru) 2006-02-24
US7649012B2 (en) 2010-01-19
EP1539730A1 (de) 2005-06-15
US20100120901A1 (en) 2010-05-13
EP2386550A1 (de) 2011-11-16
CN100513404C (zh) 2009-07-15
CN101602756B (zh) 2014-11-12
WO2004005277A1 (en) 2004-01-15
KR101087559B1 (ko) 2011-11-29
CA2767092A1 (en) 2004-01-15
JP2005533835A (ja) 2005-11-10
MXPA05000365A (es) 2005-09-20
CA2491802C (en) 2012-04-10
US20060247302A1 (en) 2006-11-02
IL190218A0 (en) 2008-11-03
CA2491802A1 (en) 2004-01-15
BRPI0312649A2 (pt) 2017-05-16
EA013371B1 (ru) 2010-04-30
KR20060002007A (ko) 2006-01-06
CN101602756A (zh) 2009-12-16
EP2386551A1 (de) 2011-11-16
CA2767092C (en) 2013-10-15
HK1083835A1 (zh) 2006-07-14
AU2003265267B2 (en) 2010-03-11
CN1675192A (zh) 2005-09-28
EP1539730A4 (de) 2007-03-28
JP2013189464A (ja) 2013-09-26
SG169236A1 (en) 2011-03-30
AU2003265267A1 (en) 2004-01-23

Similar Documents

Publication Publication Date Title
IL166108A0 (en) Novel compounds pharmaceutical compositions containing same and methods of use for same
IL173639A (en) Ppar-activating compound and pharmaceutical composition containing same
IL164987A0 (en) Proline derivatives and pharmaceutical compositions containing
IL173930A0 (en) Pharmaceutical compositions containing forms of r-baclofen
HUP0400974A3 (en) Peptide-based compounds and pharmaceutical compositions containing them
IL164455A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
HUP0401711A3 (en) N-heterocyclic inhibitors of tnf-alpha and pharmaceutical compositions containing them
IL164185A0 (en) Pharmaceutical compositions containing trifluoromethylphenyl amide derivatives
HUP0401333A3 (en) Spiropyrazole compounds and pharmaceutical compositions containing them
IL174128A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
HUP0302485A3 (en) Arylmethylamine derivatives for use as tryptase inhibitors and pharmaceutical compositions containing them
IL219396A0 (en) Compounds for the treatment of metabolic disorders and pharmaceutical compositions containing same
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
HUP0302412A3 (en) Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same
HUP0303724A3 (en) Chemokine receptors inhibitor bipiperidinyl-derivatives and pharmaceutical compositions containing them and process for preparation of the compounds
HUP0303193A3 (en) Phthalayinone-piperidino-derivatives as pde4 inhibitors and pharmaceutical compositions containing them
IL164022A0 (en) Phosphate derivatives of fluoroxindole and pharmaceutical compositions containing the same
IL166054A0 (en) Novel compounds pharmaceutical compositions containing same and methods of use for same
PL1664050T3 (pl) Neuroprotekcyjne związki bicykliczne i zawierające je kompozycje farmaceutyczne
HRP20041079A2 (en) Novel perindopril salt and pharmaceutical compositions containing same
IL166621A0 (en) Polymorph of n-methyl-n-(3-ä-3-Ä2-thienylcarbonylÜ-pyrazol-Ä1,5-alphaÜpyrimidin-7-ylüacetamide and pharmaceutical compositions containing the same
IL174249A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
PL367128A1 (en) Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
ZA200508204B (en) Pharmaceutical composition of atorvastatin
IL165839A0 (en) Compounds useful for the treatment of cancer compositions thereof and methods therewith